QuickStats: Rate of Triplet and Higher-Order Multiple Births,* < sup > , < /sup > < sup > † < /sup > by Age of Mother - National Vital Statistics System, United States, 1998 and 2022
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1394. doi: 10.15585/mmwr.mm725253a6.NO ABSTRACTPMID:38175812 | DOI:10.15585/mmwr.mm725253a6 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Source Type: research

Notes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam - Chicago, Illinois, February 2023
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1392-1393. doi: 10.15585/mmwr.mm725253a5.NO ABSTRACTPMID:38175814 | DOI:10.15585/mmwr.mm725253a5 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Authors: Paul F Ehlers Amy Deitche Leslie M Wise Sarah L Patrick Alfreda Holloway-Beth Ross Ellison Jordan Trecki Roy Gerona Michael S Wahl Source Type: research

Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months - California, January-March, 2023
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1390-1391. doi: 10.15585/mmwr.mm725253a2.NO ABSTRACTPMID:38175801 | DOI:10.15585/mmwr.mm725253a2 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Authors: Scott A Nabity Rocio Agraz-Lara Angelito Bravo Robert Benjamin Vanessa Fong C Kin Lam Chris Keh Sundari Mase Jennifer Flood Source Type: research

Second Nationwide Tuberculosis Outbreak Caused by Bone Allografts Containing Live Cells - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1385-1389. doi: 10.15585/mmwr.mm725253a1.ABSTRACTDuring July 7-11, 2023, CDC received reports of two patients in different states with a tuberculosis (TB) diagnosis following spinal surgical procedures that used bone allografts containing live cells from the same deceased donor. An outbreak associated with a similar product manufactured by the same tissue establishment (i.e., manufacturer) occurred in 2021. Because of concern that these cases represented a second outbreak, CDC and the Food and Drug Administration worked with the tissue establishment to determine that this prod...
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Authors: Jonathan M Wortham Maryam B Haddad Rebekah J Stewart Pallavi Annambhotla Sridhar V Basavaraju Scott A Nabity Isabel S Griffin Emily McDonald Elizabeth M Beshearse Marissa K Grossman Kimberly R Schildknecht Helene M Calvet Chris E Keh Jeffrey M Percak Myro Source Type: research

QuickStats: Rate of Triplet and Higher-Order Multiple Births,* < sup > , < /sup > < sup > † < /sup > by Age of Mother - National Vital Statistics System, United States, 1998 and 2022
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1394. doi: 10.15585/mmwr.mm725253a6.NO ABSTRACTPMID:38175812 | DOI:10.15585/mmwr.mm725253a6 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Source Type: research

Notes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam - Chicago, Illinois, February 2023
MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1392-1393. doi: 10.15585/mmwr.mm725253a5.NO ABSTRACTPMID:38175814 | DOI:10.15585/mmwr.mm725253a5 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - January 4, 2024 Category: Epidemiology Authors: Paul F Ehlers Amy Deitche Leslie M Wise Sarah L Patrick Alfreda Holloway-Beth Ross Ellison Jordan Trecki Roy Gerona Michael S Wahl Source Type: research

SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research

Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1371-1376. doi: 10.15585/mmwr.mm7251a3.ABSTRACTNursing home residents are at risk for becoming infected with and experiencing severe complications from respiratory viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Fall 2023 is the first season during which vaccines are simultaneously available to protect older adults in the United States against all three of these respiratory viruses. Nursing homes are required to report COVID-19 vaccination coverage and can voluntarily report influenza and RSV vaccination coverage among residents to CDC's Nationa...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Hannah E Reses Heather Dubendris Lori Haas Kira Barbre Sushmitha Ananth Theresa Rowe Elizabeth Mothershed Elisha Hall Ryan E Wiegand Megan C Lindley Sarah Meyer Suchita A Patel Andrea Benin Seth Kroop Arjun Srinivasan Jeneita M Bell Source Type: research

Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research

Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1377-1382. doi: 10.15585/mmwr.mm7251a4.ABSTRACTDuring the 2023-24 respiratory virus season, the Advisory Committee on Immunization Practices recommends influenza and COVID-19 vaccines for all persons aged ≥6 months, and respiratory syncytial virus (RSV) vaccine is recommended for persons aged ≥60 years (using shared clinical decision-making), and for pregnant persons. Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of U.S. adults aged ≥18 years, are used to monitor influenza, COVID-19, and RSV vaccination cove...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Carla L Black Jennifer L Kriss Hilda Razzaghi Suchita A Patel Tammy A Santibanez Mehreen Meghani Ashley Tippins Shannon Stokley Kevin Chatham-Stephens Nicole F Dowling Georgina Peacock James A Singleton Source Type: research

QuickStats: Age-Adjusted Percentage* of Adults Aged ≥18 Years Who Reported Their Level of Satisfaction with Life, < sup > † < /sup > by Disability Status < sup > § < /sup > - National Health Interview Survey, < sup > ¶ < /sup > United States, 2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1383. doi: 10.15585/mmwr.mm7251a5.NO ABSTRACTPMID:38127681 | PMC:PMC10754265 | DOI:10.15585/mmwr.mm7251a5 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Source Type: research

SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research

Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1371-1376. doi: 10.15585/mmwr.mm7251a3.ABSTRACTNursing home residents are at risk for becoming infected with and experiencing severe complications from respiratory viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Fall 2023 is the first season during which vaccines are simultaneously available to protect older adults in the United States against all three of these respiratory viruses. Nursing homes are required to report COVID-19 vaccination coverage and can voluntarily report influenza and RSV vaccination coverage among residents to CDC's Nationa...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Hannah E Reses Heather Dubendris Lori Haas Kira Barbre Sushmitha Ananth Theresa Rowe Elizabeth Mothershed Elisha Hall Ryan E Wiegand Megan C Lindley Sarah Meyer Suchita A Patel Andrea Benin Seth Kroop Arjun Srinivasan Jeneita M Bell Source Type: research

Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research

Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1377-1382. doi: 10.15585/mmwr.mm7251a4.ABSTRACTDuring the 2023-24 respiratory virus season, the Advisory Committee on Immunization Practices recommends influenza and COVID-19 vaccines for all persons aged ≥6 months, and respiratory syncytial virus (RSV) vaccine is recommended for persons aged ≥60 years (using shared clinical decision-making), and for pregnant persons. Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of U.S. adults aged ≥18 years, are used to monitor influenza, COVID-19, and RSV vaccination cove...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Carla L Black Jennifer L Kriss Hilda Razzaghi Suchita A Patel Tammy A Santibanez Mehreen Meghani Ashley Tippins Shannon Stokley Kevin Chatham-Stephens Nicole F Dowling Georgina Peacock James A Singleton Source Type: research